Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response Presented ByDr Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 1/2, IMCgp100-202 ConferenceESMO 2021 19 November, 2021 09:09
Promising first-in-human trial of epcoritamab in B-NHL Presented ByDr Martin Hutchings, Copenhagen University Hospital, Denmark TrialPhase 1/2, GEN3013 ConferenceEHA 2020 9 September, 2020 12:30
